Literature DB >> 14640913

Replacement therapy in Addison's disease.

Kristian Løvås, Eystein S Husebye.   

Abstract

Addison's disease or primary adrenal insufficiency is a rare disease, which is usually caused by autoimmune destruction of the adrenal cortex. The clinical picture is caused by deficiency of cortisol and aldosterone. These deficiencies are accompanied by adrenal androgen depletion of yet unknown significance. The current therapy is the replacement of glucocorticoids and mineralocorticoids, but the available drugs do not restore the normal diurnal variations in serum hormone levels. The clinical consequences of the grossly unphysiological replacement therapy are largely unknown. Many patients with Addison's disease on standard replacement therapy complain of fatigue, weariness, and reduced stress tolerance. One particular concern has been negative effects on both bone metabolism due to over-replacement of glucocorticoids and androgen depletion. This review discusses the evidence for the current drug and dosage recommendations. Current recommended daily starting dose for hydrocortisone and cortisone acetate are 20 and 25 mg, respectively, divided into two or preferably three doses. The mineralocorticoid depletion should be treated with fludrocortisone 0.05-2.0 mg/day [DOSAGE ERROR CORRECTED]. Replacement of dehydroepiandrosterone 20-50 mg has been advocated in adrenal failure, but the evidence for benefit is weak.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14640913     DOI: 10.1517/14656566.4.12.2145

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

1.  Hypothalamic-Pituitary-Adrenal Reactivity to Acute Stress: an Investigation into the Roles of Perceived Stress and Family Resources.

Authors:  Ezemenari M Obasi; Elizabeth A Shirtcliff; Lucia Cavanagh; Kristen L Ratliff; Delishia M Pittman; Jessica J Brooks
Journal:  Prev Sci       Date:  2017-11

2.  Cortisol-dependent stress effects on cell distribution in healthy individuals and individuals suffering from chronic adrenal insufficiency.

Authors:  Ashley M Geiger; Kenneth P Pitts; Joachim Feldkamp; Clemens Kirschbaum; Jutta M Wolf
Journal:  Brain Behav Immun       Date:  2015-07-14       Impact factor: 7.217

3.  Biphasic effects of dexamethasone on glycogen metabolism in primary cultured rat hepatocytes.

Authors:  X-F Zheng; L Liu; J Zhou; M-Y Miao; J-R Zhou; D Zhu; Z-F Xia; C-L Jiang
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

Review 4.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

Review 5.  Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence.

Authors:  Roberto Perniola; Alessandra Fierabracci; Alberto Falorni
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

6.  9β Polymorphism of the glucocorticoid receptor gene appears to have limited impact in patients with Addison's disease.

Authors:  Ian Louis Ross; Collet Dandara; Marelize Swart; Miguel Lacerda; Desmond Schatz; Dirk Jacobus Blom
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

Review 7.  Dynamics of ACTH and Cortisol Secretion and Implications for Disease.

Authors:  Stafford L Lightman; Matthew T Birnie; Becky L Conway-Campbell
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.